Background: The incidence of thyroid cancer is increasing worldwide at
an alarming rate. BRAFV600E mutation is described to be associated with
a worse prognostic of thyroid carcinomas, as well as extrathyroidal
invasion and increased mortality. Objective: To our knowledge, there
are no reported studies neither from Morocco nor from other Maghreb
countries regarding the prevalence of BRAFV600E mutation in thyroid
carcinomas. Here we aim to evaluate the frequency of BRAFV600E oncogene
in Moroccan thyroid carcinomas. Methods: In this Single-Institution
retrospective study realized in the Anatomic Pathology and Histology
Service in the Military Hospital of Instruction Mohammed V
\u2018HMIMV\u2019 in Rabat, we report, using direct genomic
sequencing, the assessment of BRAFV600E in 37 thyroid tumors. Results:
We detected BRAFV600E mutation exclusively in Papillary Thyroid
Carcinomas \u2018PTC\u2019 with a prevalence of 28% (8 PTC out 29
PTC). Like international trends, Papillary Thyroid Carcinomas
\u2019PTC\u2019 is more frequent than Follicular Thyroid Carcinomas
\u2018FTC\u2019 and Anaplastic Thyroid Carcinomas \u2018ATC\u2019
(29 PTC, 7 FTC and 1 ATC). Conclusion: Our finding gives to the
international community the first estimated incidence of this oncogene
in Morocco showing that this prevalence falls within the range of
international trends (30% to 90%) reported in distinct worldwide
geographic regions